Mechelen, Belgium; 1 February 2017 – Galapagos NV announces dosing of the first patient with cystic fibrosis Class III with novel CF corrector GLPG2222 as an add-on to Kalydeco® in a Phase 2a study. Galapagos further announced the opening of an Investigational New Drug file with the US Food & Drug Administration for GLPG2222, triggering a $10 million milestone payment.
Category: Food and Drug Administration
BRIEF-Index Pharmaceuticals enters agreement with CRO for the conduct study
* Said on Tuesday decided to invest 75,000 euros in a capital increase of Applied Research Using Omic Sciences and reach 1.5 percent in the company